

SEPTEMBER 2025

Marketing communication

INVESTMENT OBJECTIVE

To achieve capital appreciation on an absolute and relative basis over the medium to long-term horizon through investment in Swiss equities with a focus on innovative companies that are leaders in their markets.

PORTFOLIO REVIEW

Swiss equities underperformed other markets in September. Once again, and as was the case during the prior month, large caps held up relatively well, with the SMI shedding only 0.5%, while small- and mid-caps accounted for most of the decline, losing 2.5%. Combined with the Swiss franc appreciation against US dollar and a still uncertain economic environment, the worrisome situation surrounding the new US tariffs being imposed on Swiss exporters is weighing on the second half corporate outlook. There are growing fears of mixed results, which may well lead to downward revisions in analyst estimates when Swiss companies release their third-quarter figures.

The Bruellan Dynamic Swiss fund closed the month down 0.9%, in line with the SPI.

Among the performance detractors figure some medical technology names, such as Straumann (-10%), which has been under pressure for several weeks. Until recently, and unlike the pharmaceutical sector, medical device manufacturers had been relatively spared from tariffs thanks to the Nairobi Protocol, which involves exemptions on products intended for people with disabilities. However, the US administration has now decided to take a closer look at this sector, via the launch of a Section 232 investigation to determine whether the country's dependence on medical technology imports poses a risk to national security. If so, the imposition of specific customs duties could ultimately be justified.

The best monthly performers include two Swiss suppliers to the semiconductor sector, VAT (+20%) and Comet (+12%). Buoyed by Nvidia's record results and announcements of massive investments by major technology players in recent weeks, the entire sector has rebounded sharply on both sides of the Atlantic. Also noteworthy are the strong bounces of Interroll (+11%), which reported an improvement in its order book this summer, and Richemont (+11%), which is recovering after a temporary dip.

RISK & REWARD

1	2	3	4	5	6	7
Low			High			

FUND FACTS

Domicile	Switzerland
Inception date	19 January 2015
Currency	CHF
Lead Manager	Anick Baud
Co-Manager	Florian Marini CFA, CMT
Fund size*	CHF 35 Millions
Liquidity (sub./red.)	Daily
Min. Investment	Retail: 1000 CHF Instit.: 1 million CHF

Entry/exit fees	0.0% / 0.0%
Management fees	1.2%-0.8%
Performance fees	20%
High Water Mark	Yes
Benchmark	SPI Index
ISIN	Retail: CH0253810144 Instit.: CH0253810169


Bloomberg	Retail: BDFSECA SW Instit.: BDFSECB SW
-----------	---

NAV	Retail: 2126.86 Instit.: 2169.74
-----	-------------------------------------

* the total strategy size is CHF 66 millions

Not all the costs are presented, further information can be found in the prospectus or equivalent.

NET PERFORMANCE AND ANNUAL PERFORMANCE IN CHF



	Fund	SPI Index	+/-
1 Month	-0.9%	-0.9%	0.0%
3 Months	-0.4%	1.3%	-1.7%
YTD	7.5%	8.2%	-0.8%
Since inception	117.0%	108.3%	8.7%

Source: All data and graphs throughout the document from Bruellan.

Past performance may not be a reliable guide to future performance. All forms of investment involve risk.


The benchmark index is the SPI Index.

Please refer to the end of the document mentioned for performance comparison purposes.


STATISTICS

	Fund	SPI Index
Leading PE	22.1	17.5
EV/EBITDA	17.9	11.9
P/Book	6.1	2.0
Dividend Yield	2.1%	2.7%
ROE	27.0%	8.2%
Debt/Equity	56.6%	54.4%
Interest Coverage	15.5	8.3
Beta	1.0	1.0
Volatility	14.3%	12.4%

ALLOCATION BY MARKET CAP



ALLOCATION BY SECTOR



FUND COMPLEMENTARY DETAILS

Administrator	CACEIS (Switzerland) SA, Rte de Signy 35, CH-1260 Nyon
Investment Manager	Bruellan SA
Custodian	CACEIS (Switzerland) SA, Rte de Signy 35, CH-1260 Nyon
Auditor	KPMG

TOP 10 HOLDINGS

	Sector	Weight
NOVARTIS AG-REG	Health Care	10.0%
NESTLE SA-REG	Consumer Staples	9.8%
ROCHE HOLDING AG-GENUSSCHEIN	Health Care	9.1%
GALDERMA GROUP AG	Health Care	4.8%
ZURICH INSURANCE GROUP AG	Financials	4.5%
BELIMO HOLDING AG-REG	Industrials	4.4%
LONZA GROUP AG-REG	Health Care	4.3%
CIE FINANCIERE RICHEMO-A REG	Consumer Discretionary	4.0%
SWISSQUOTE GROUP HOLDING-REG	Financials	3.9%
GIVAUDAN-REG	Materials	3.8%
Total		58.7%

Total number of Holdings

25

CONTACT

BRUELLAN SA
Rue Pécolat 1
CH-1201 Genève
Tél: +41 22 817 18 55
bam@bruellan.ch

Disclaimer: Bruellan SA has a FINMA authorisation as a collective asset manager. This publication is a promotional document within the meaning of art. 68 LSFIn, it is not independent research. It is solely intended to provide information on the funds in question and does not constitute an offer to buy or sell, investment advice or a recommendation regarding investment or other decisions. The funds may be subject to sales restrictions applicable to certain countries or individuals. It is the responsibility of each investor to be aware of the terms and conditions applicable to each product. This publication is directed only at persons authorised to receive it under the regulations in force in their country of domicile.

The information contained herein is based on sources believed to be reliable. This is a marketing communication. Bruellan cannot guarantee its completeness and accuracy and accepts no liability for any damage that may result from actions taken on the basis of the information published in this document. The information reflects the situation on the day of publication. We have classified this product as 5 out of 7, which is a medium - high risk class. Please refer to the prospectus for more information on the specific risks relevant to this product not included in the summary indicator.

Investment decisions should always be made on the basis of a detailed source of information, in particular the fund prospectus. The prospectus, the articles of association, the key information document, the subscription form and the latest annual and semi-annual reports can be obtained (free of charge) from the Swiss representative, Fund Partner Solutions (Suisse) SA, 60, route des Acacias, 1211 Geneva. Please refer to the prospectus and information document of the fund before making any final investment decisions. You can obtain a summary of investors rights to the following link:

<https://www.pictet.com/content/dam/www/documents/legal-and-notes/fundpartner-solutions/fps-summary-of-Investors-rights.pdf>. The decision to invest in the promoted fund should take into account all the characteristics or objectives of the promoted fund as described in its prospectus. Information on sustainability-related aspects provided in relation to the promoted fund could be found on the following link:

<https://assetservices.group.pictet/asset-services/esg-disclosures?isin=LU1118008553>. Incorporation of extra-financial risks into the investment decision process may result in underweighting of profitable investments from the sub-fund's investment universe and may also lead the management of the sub-fund to underweight investments that will continue to perform. The Fund has been classified as a financial product subject to Article 8 of Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial sector (the "SFDR"). The Fund promotes, among other characteristics, environmental or social characteristics, or a combination of those characteristics, provided that the companies in which the investments are made follow good governance practices. Performance disclosures: the published performance represents past data. Past performance may not be a reliable guide to future performance. There is no guarantee that the same yields will be obtained in the future. The value and income of any of your investments may fluctuate with market conditions and may lose some or all its value. The fund may be affected by changes in currency exchange rates, which can have an adverse effect on the value or income of the fund. Future performance is also subject to taxation which depends on the personal situation of each investor and which may change in the future. : All performance data are based on net performance and take no account of commissions, fees or other costs charged when units are issued and redeemed.